Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular, Molecular, and Tumor Biology 2: Angiogenesis Inhibitors II

Synergistic anti-tumor activity of paclitaxel with CNTO 95, a fully human monoclonal antibody that targets αv integrins

Jeffrey A. Nemeth, Zhao Zhou, Eva Emmell, Celia Sharp, Marian T. Nakada and Mohit Trikha
Jeffrey A. Nemeth
Centocor, Malvern, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhao Zhou
Centocor, Malvern, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Emmell
Centocor, Malvern, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celia Sharp
Centocor, Malvern, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marian T. Nakada
Centocor, Malvern, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohit Trikha
Centocor, Malvern, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2004
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 45, 2004

Abstract

71

CNTO 95 is a fully human monoclonal antibody which binds and neutralizes αv integrins. We recently demonstrated that CNTO 95 possesses both anti-angiogenic and direct anti-tumor activity against human melanoma xenografts in vivo. In the present study CNTO 95 was combined with the chemotherapeutic compound paclitaxel, which itself exhibits both anti-angiogenic and anti-tumor effects. Treatment of human endothelial cells in culture with paclitaxel and CNTO 95 resulted in a dose-dependent decrease in cell proliferation and an increase in apoptosis. These effects were more pronounced with the combination than with either agent alone. Similarly, the combination of paclitaxel with CNTO 95 was more effective than either agent alone in reducing proliferation and inducing apoptosis of human melanoma cells. For in vivo analysis, nude rats were inoculated subcutaneously with human melanoma cells, and experimental therapy was initiated when tumors reached 150-200 mm3. In this model, CNTO 95 inhibits tumor cell and host angiogenic integrins. Intensive dosing with paclitaxel for one week (escalating to 15 mg/kg) caused a 52% reduction in tumor growth by day 16, and provided a tumor growth delay of 12 days. While CNTO 95 by itself had little effect in this model, the combination of paclitaxel and CNTO 95 (10 mg/kg weekly) showed greatly enhanced activity, causing a 71% reduction in tumor size by day 16 and a growth delay of 24 days. Fractional tumor volume analysis revealed synergy between the two agents. Together, these data support the hypothesis that combining biologic agents with chemotherapeutics will enhance anti-tumor efficacy.

  • American Association for Cancer Research
Previous
Back to top
April 2004
Volume 64, Issue 7 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Synergistic anti-tumor activity of paclitaxel with CNTO 95, a fully human monoclonal antibody that targets αv integrins
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Synergistic anti-tumor activity of paclitaxel with CNTO 95, a fully human monoclonal antibody that targets αv integrins
Jeffrey A. Nemeth, Zhao Zhou, Eva Emmell, Celia Sharp, Marian T. Nakada and Mohit Trikha
Cancer Res April 1 2004 (64) (7 Supplement) 17;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synergistic anti-tumor activity of paclitaxel with CNTO 95, a fully human monoclonal antibody that targets αv integrins
Jeffrey A. Nemeth, Zhao Zhou, Eva Emmell, Celia Sharp, Marian T. Nakada and Mohit Trikha
Cancer Res April 1 2004 (64) (7 Supplement) 17;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • TIMP-2-induced growth inhibition of FGF-2-stimulated endothelial cells is mediated by SHP-1-dependent induction of p27Kip1
  • Induction of tissue-type plasminogen activator gene transcription by Neovastat, a multifunctional anti-angiogenic drug
  • Akt as a signaling intermediate between endothelial alpha-v integrins and p53
Show more Cellular, Molecular, and Tumor Biology 2: Angiogenesis Inhibitors II
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement